<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; LIFE</title>
	<atom:link href="http://www.stockbloghub.com/tag/life/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(QGEN) Qiagen Beats Earnings Forecasts &#8211; Reiterates Outllook</title>
		<link>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817</link>
		<comments>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99817</guid>
		<description><![CDATA[Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating the Zacks Consensus Estimate of 19 cents as well as the year-ago quarter earnings by a couple of cents. The improvement in the bottom line was driven by double–digit sales growth and efficient cost management. In the fourth quarter, all the operational regions of the company delivered double-digit growth at CER. Region wise, Americas (47% of revenues) witnessed a 15% increase in sales at CER, driven by strong contributions from the US, Brazil and Canada. However, revenues from Europe- Middle East-Africa (34% of sales) and Asia-Pacific /Japan (18% of sales) increased 12% and 18% at CER, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ILMN) Two Major Biotech Trends In 2012</title>
		<link>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438</link>
		<comments>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438#comments</comments>
		<pubDate>Thu, 19 Jan 2012 23:34:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90438</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate a few tons of filets and guzzled thousands of gallons of Starbucks coffee. What makes the conference such a big deal is that it’s the largest and most important investor event of the year in the healthcare sector. There are other healthcare conferences put on by investment banks, but nothing comes close to the quality and number of companies and attendees at JPM. There were two important takeaways that emerged from the conference – themes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Shares Maintained at Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/30/tmo-thermo-fisher-scientific-shares-maintained-at-neutral/87822</link>
		<comments>http://www.stockbloghub.com/2011/11/30/tmo-thermo-fisher-scientific-shares-maintained-at-neutral/87822#comments</comments>
		<pubDate>Wed, 30 Nov 2011 20:05:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87822</guid>
		<description><![CDATA[Recently, we reiterated our Neutral recommendation on Thermo Fisher Scientific (TMO) with a target price of $47.00. Thermo Fisher continues to be focused on effectively deploying its cash balance to create value through share buybacks and suitable acquisitions. Significant acquisitions include that of Dionex Corporation and Phadia. The former brings in ion and liquid chromatography portfolio while the latter is a leading player in allergy and autoimmunity diagnostics. Thermo Fisher is actively focused on improving its operating margin. The initiatives include adoption of Practical Process Improvement (PPI) and PPI-Lean projects, continued tight cost control on discretionary spending and infrastructure optimization that includes reduced footprint and expanded low-cost region (LCR) manufacturing (China, Mexico and Eastern Europe). Of Thermo Fisher’s four end markets – Industrial/Applied, Biopharma, Healthcare and Government/Academic – the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/tmo-thermo-fisher-scientific-shares-maintained-at-neutral/87822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Added in Russell 1000 and 3000</title>
		<link>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895</link>
		<comments>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:57:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77895</guid>
		<description><![CDATA[Recently, Qiagen (QGEN) announced that it has been included in the Russell 1000 and the Russell 3000 Indices. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe and includes approximately 1,000 of the largest securities based on a combination of their market cap and current index. On the other hand, the Russell 3000 index evaluates the performance of the 3,000 largest U.S. companies by market capitalization. The constituents of the indices will remain in place for a year. Qiagen is a leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.  Over the years, the company  has developed a comprehensive portfolio of more than 500 proprietary, consumable products, and automated solutions for sample collection.  The company specializes in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Ties Up with Pharma Majors</title>
		<link>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570</link>
		<comments>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[Neuberger Berman High Yield Strategies Fund]]></category>
		<category><![CDATA[NGS]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77570</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently strengthened its newly created Technology Strategy Board grant consortium with the inclusion of the R&#38;D divisions of AstraZeneca (AZN) and Johnson &#38; Johnson (JNJ). The group expects this grant to fund the development of a commercial multi-gene next generation sequencing test, which will provide comprehensive molecular profiles of tumors and identify treatment options. Life Technologies believes that the test will increase the speed and accuracy of cancer treatment. With the application of the next generation sequencing (NGS) and informatics, this genomic test will be commercially available in the global market. This program will attract additional pharmaceutical clinical trial investments in UK that should prove to be a major source of international investment. Thus, the consortium expects this new program to add life to the economic condition ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex MAGPIX Earns Stevie Award for Business</title>
		<link>http://www.stockbloghub.com/2011/06/26/lmnx-luminex-magpix-earns-stevie-award-for-business/77472</link>
		<comments>http://www.stockbloghub.com/2011/06/26/lmnx-luminex-magpix-earns-stevie-award-for-business/77472#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:26:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77472</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has clinched two American Business Awards (“Stevie Awards”) for its flagship MAGPIX analytical instrument. The Stevie Awards were created to honor organizations of all types and sizes and business people in recognition of their positive contributions and achievements in the workplace globally. The Texas-based company was crowned the “Most Innovative Company of the Year (for companies with less than 2,500 employees)” and “Business Innovation of the Year” awards for its innovative MAGPIX instrument. The awards were presented at a gala event at the New York Marriott Marquis Hotel in Times Square. Apart from Luminex, other notable winners of the Stevie Award include Apple Inc. (AAPL), Whole Foods Market Inc. (WFM), Cisco Systems Inc. (CSCO), Dell Inc (DELL), General Electric (GE) and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/lmnx-luminex-magpix-earns-stevie-award-for-business/77472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Hopeful of Ipsogen Takeover</title>
		<link>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626</link>
		<comments>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626#comments</comments>
		<pubDate>Mon, 20 Jun 2011 00:33:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76626</guid>
		<description><![CDATA[Recently, Qiagen (QGEN) entered into an agreement to acquire 47% stake in France based Ipsogen at €12.90 per share. Thereafter, Qiagen wishes to make a public offer to fully acquire the company. With Ipsogen, Qiagen would have access to a wide portfolio of biomarkers targeted to patients suffering from with blood cancer. Ipsogen recorded 24% sales growth in 2010 to €8.4 million (approximately $11 million). The total value on fully acquiring Ipsogen would stand at €70 million (fully diluted) or $101 million (at exchange rate of €1.00 = $1.44). The whole transaction (including the public offer) is expected to be completed by the third quarter of 2011. Qiagen would fund this acquisition using its existing cash balance. The transaction, on an adjusted basis, would be slightly dilutive to adjusted EPS ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Deals with Luminex</title>
		<link>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397</link>
		<comments>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397#comments</comments>
		<pubDate>Tue, 14 Jun 2011 18:56:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75397</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently entered into a global sales and distribution agreement with Luminex Corporation (LMNX) to access the latter’s award-winning multiplexing instrument MAGPIX to analyze proteins for research. This partnership is expected to be beneficial for MAGPIX as Life caters to scientists and researchers worldwide. On the other hand, Life expects MAGPIX to expand its cutting-edge antibody content across a broad range of protein quantitation needed in basic and clinical research. MAGPIX (launched in July 2010) is a compact, multiplex analyzer that helps efficient detection of 50 different analytes on a single sample, including proteins and nucleic acids. This product received the Medical Design Excellence Award in 2011 for its innovative design and contribution and recently received CE IVD mark in Europe. Life earns revenues from three divisions ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Tops Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741</link>
		<comments>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741#comments</comments>
		<pubDate>Thu, 12 May 2011 00:51:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73741</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, posted first-quarter fiscal 2011 earnings per share of 11 cents, comfortably beating the Zacks Consensus Estimate of 6 cents and exceeding the year-ago earnings of 5 cents. Profit more than doubled year over year to roughly $4.5 million owing to higher sales. Revenues shot up 30% year over year to $43.3 million, ahead of the Zacks Consensus Estimate of $40 million. The growth was led by solid consumables and assay sales. Consumable sales rocketed 53% to a record $15 million, buoyed by healthy demand from the company’s major partners. System revenues climbed 15% to $7.7 million, helped by healthy shipments of multiplexing analyzers. The Texas-based company shipped 197 analyzers (including 38 MAGPIX systems) in the quarter, flat year over year. Royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Affymetrix Analyst Initiates Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708</link>
		<comments>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708#comments</comments>
		<pubDate>Sun, 17 Apr 2011 18:39:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[CBMX]]></category>
		<category><![CDATA[CombiMatrix Corporation]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71708</guid>
		<description><![CDATA[We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus Estimate while profit surged 42% year over year as lower costs more than offset a decline in sales. California-based Affymetrix is a leading provider of microarray-based products and services to the global research community. Along with Illumina Inc. (ILMN), it is one of the two major providers of microarray technologies primarily used in the field of genetic research. Affymetrix has expertise in gene expression monitoring arrays, which are used to identify correlations between genes, determine their biological functions, and identify patterns that enable more accurate disease classification. It has a dominant position in the gene expression market and enjoys a recurring ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex MAGPIX Wins MDEA</title>
		<link>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348</link>
		<comments>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71348</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, recently received the prestigious Medical Design Excellence Award (“MDEA”) for its MAGPIX analytical instrument. MDEA, organized by the leading business-to-business media company UBM Canon, is a premier awards program which recognizes the achievements of medical devices manufacturers. MAGPIX was recognized in the “In Vitro Diagnostics” category of the award, through a comprehensive review by a multi-disciplinary jury panel, for its innovative design and contribution. The award will be presented at a ceremony on June 8, 2011, at the Jacob K. Javits Convention Center in New York City. The MAGPIX system (launched in July 2010) leverages Luminex’s proprietary open-architecture xMAP technology and is capable of producing up to 50 tests on a single sample. The versatile multiplexing platform can be used to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AEO) Company News for February 04, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/02/06/aeo-company-news-for-february-04-2011-corporate-summary/66398</link>
		<comments>http://www.stockbloghub.com/2011/02/06/aeo-company-news-for-february-04-2011-corporate-summary/66398#comments</comments>
		<pubDate>Sun, 06 Feb 2011 21:55:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Apparel Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AEO]]></category>
		<category><![CDATA[American Eagle Outfitters Inc.]]></category>
		<category><![CDATA[Ameriprise Financial Inc.]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[EL]]></category>
		<category><![CDATA[Estee Lauder Companies Inc.]]></category>
		<category><![CDATA[HAR]]></category>
		<category><![CDATA[Harman International Industries Inc]]></category>
		<category><![CDATA[K]]></category>
		<category><![CDATA[Kellogg Company]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[MA]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[Mastercard Incorporated]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>
		<category><![CDATA[THQ Inc.]]></category>
		<category><![CDATA[THQI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66398</guid>
		<description><![CDATA[• MasterCard (NYSE:MA) reported Q4 EPS of $3.16, lower than the Zacks Consensus Estimate of $3.98 per share. Revenues for the quarter rose 10.7% year-over-year to $1.44 billion, beating the Zacks Consensus Estimate of $1.436 billion • Kellogg Company (NYSE:K) reported Q4 EPS of $0.51, lower than the Zacks Consensus Estimate of $1.06 per share. Revenues for the quarter fell 1% year-over-year to $2.86 billion, below the Zacks Consensus Estimates of $3.350 billion • Macy&#8217;s (NYSE:M) reported higher figures for its same store sales. Same-store sales in January increased 2.6% against expectations of 2.1% rise. Online sales of the company rose 27.2% in January • Same store sales of American Eagle (NYSE:AEO) fell 6% in January, lower than the expected figure of 7.6%. The company said it sees Q4 EPS on the high end ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/06/aeo-company-news-for-february-04-2011-corporate-summary/66398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Earns FDA Approval for New Diagnostic Test</title>
		<link>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911</link>
		<comments>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911#comments</comments>
		<pubDate>Thu, 18 Nov 2010 19:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[China Petroleum & Chemical Corporation]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SNP]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59911</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an individual&#8217;s response to drugs. The test, dubbed the xTAG CYP2D6 Kit, has been designed to bring in the personalized medicine approach by helping physicians to identify and manage patients for whom they may prescribe therapies which are metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. The xTAG CYP2D6 Kit will be marketed throughout the U.S. through Luminex Molecular Diagnostics (“LMD”), a unit of the company’s Assay segment. The CYP2D6 enzyme is involved in the metabolism of many prescription drugs. A segment of the population may carry a slow-acting or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442</link>
		<comments>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442#comments</comments>
		<pubDate>Tue, 16 Nov 2010 04:50:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59442</guid>
		<description><![CDATA[We downgrade our recommendation on Luminex Corporation (LMNX) to Underperform following the company’s lower-than-expected third quarter results and a less favorable outlook. Third-quarter fiscal 2010 adjusted loss per share of 2 cents missed the Zacks Consensus Estimate of earnings of 4 cents. Losses swelled 19% year over year as revenue growth was offset by higher costs and tax. Top line improved on solid consumables and assay sales, but missed the Zacks Consensus Estimate. Annualized decline in the shipments of analytical instruments contributed to lower system sales in the quarter.The company has narrowed its revenue forecast for fiscal 2010. Luminex develops, manufactures and markets proprietary biological testing technologies, which have applications across the life sciences industry. The company’s proprietary open-architecture xMAP technology enables fast, cost-effective and accurate conduct and analysis of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters Corporation Earnings Slightly Below The Street</title>
		<link>http://www.stockbloghub.com/2010/11/03/wat-waters-corporation-earnings-slightly-below-the-street/56703</link>
		<comments>http://www.stockbloghub.com/2010/11/03/wat-waters-corporation-earnings-slightly-below-the-street/56703#comments</comments>
		<pubDate>Wed, 03 Nov 2010 18:20:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56703</guid>
		<description><![CDATA[Waters Corp. (WAT) released its third quarter earnings before the market opened today, reporting earnings from continuing operation of 96 cents, slightly below the Zacks Consensus Estimate of 97 cents.  Earnings in the quarter increased by 21.5% from 79 cents in the third quarter of 2009. Revenue On the top line, WAT outperformed the Zacks Consensus Estimate of $397 million by merely $4 million, reporting total revenue of $401 million.  Total revenue during the quarter increased by 7% year over year as the company delivered solid performance in its pharmaceutical and chemical end markets. Foreign currency translation negatively impacted the company’s sales by 2%. Sales in the quarter were primarily driven by delivery of new instrument systems Incorporatedluding ACQUITY H-Class UPLC and increased demand for the research-focused mass spectrometry products. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/wat-waters-corporation-earnings-slightly-below-the-street/56703/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters  Corporation Third Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/10/25/wat-waters-corporation-third-quarter-2010-earnings-preview/56397</link>
		<comments>http://www.stockbloghub.com/2010/10/25/wat-waters-corporation-third-quarter-2010-earnings-preview/56397#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:48:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56397</guid>
		<description><![CDATA[Waters Corp. (WAT) is slated to report its third quarter 2010 earnings on October 26, 2010 before the opening bell. The current Zacks Consensus Estimate for the third quarter is 97 cents per share, representing a year-over-year growth of 4.3%. Waters has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average surprise of 3.55%. Second Quarter Recap Waters Corp.’s second quarter 2010 per share from continuing operations was 90 cents, an increase of 25% from 72 cents in the second quarter of 2009. On the top line, Waters outperformed the Zacks Consensus Estimate by merely $3 million, reporting total revenue of $391 million.  Total revenue during the quarter increased by 8% year over year as the company experienced strong demand for its products in key ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/wat-waters-corporation-third-quarter-2010-earnings-preview/56397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit</title>
		<link>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446</link>
		<comments>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:13:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35446</guid>
		<description><![CDATA[I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors used to perform lobotomies on people with mental problems. By 2020, there will be new drugs on the market and technologies developed that weren’t even dreamed about at the turn of the 21st century. New discoveries will extend life, or cure diseases that even the most forward-thinking scientists couldn’t have imagined just a short time ago. And fortunes will be made as a result. The question is: How do you grab your piece of the pie? Blasting Tumors… Bagging Profits If you’re ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Corporation Sells Mass Spectrometry Business</title>
		<link>http://www.stockbloghub.com/2010/02/08/life-life-technologies-corporation-sells-mass-spectrometry-business/27377</link>
		<comments>http://www.stockbloghub.com/2010/02/08/life-life-technologies-corporation-sells-mass-spectrometry-business/27377#comments</comments>
		<pubDate>Tue, 09 Feb 2010 03:34:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[MDZ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27377</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently completed the sale of its mass spectrometry business to Danaher Corporation (DHR) for $450 million in cash, subject to a conventional working capital adjustment. Danaher also acquired Life’s joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (MDZ). We view Life’s decision to divest its Mass Spectrometry business as a smart strategic move. This decision should allow the company to focus on the high growth molecular and genomics markets. Moreover, the company will be able to utilize a part of the sale proceeds for the repayment of its significant debt. Life recently reported strong results for the fourth quarter of 2009. The company reported fourth quarter earnings of 80 cents per share, well above the Zacks Consensus Estimate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/life-life-technologies-corporation-sells-mass-spectrometry-business/27377/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DHR) Danaher Corporation Exceeds Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/29/dhr-danaher-corporation-exceeds-expectations/26459</link>
		<comments>http://www.stockbloghub.com/2010/01/29/dhr-danaher-corporation-exceeds-expectations/26459#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Conglomerates]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26459</guid>
		<description><![CDATA[Danaher Corp. (DHR) reported fourth-quarter earnings from continuing operations of $1.08 per share, which excludes additional restructuring charges, beating the Zacks Consensus Estimate of $1. Quarterly sales were $3.1 billion, 1.5% less than the $3.2 billion reported in the year-ago quarter. Core revenues declined 9% in the quarter, compared to the fourth quarter of 2008. It was heartening to note the continued sequential end market improvements in the fourth quarter, as well as solid execution on the restructuring initiatives undertaken throughout the year.  The company’s continued focus on internal growth investments, new product introductions and strategic M&#38;A opportunities give it enough impetus to outperform in 2010 and over the long term. Professional instrumentation segment was the largest revenue earner with $1.2 billion in the quarter followed by Medical Technologies with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/dhr-danaher-corporation-exceeds-expectations/26459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Corporation Beats Expectations &#8211; Outlook Positive</title>
		<link>http://www.stockbloghub.com/2010/01/28/life-life-technologies-corporation-beats-expectations-outlook-positive/26320</link>
		<comments>http://www.stockbloghub.com/2010/01/28/life-life-technologies-corporation-beats-expectations-outlook-positive/26320#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:30:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LIMS]]></category>
		<category><![CDATA[Starlims Technologies Ltd]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26320</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) reported fourth quarter earnings of 80 cents per share, well above the Zacks Consensus Estimate of 72 cents. The company reported earnings of 82 cents in the year-ago period. For the full year, Life reported earnings of $3.04, beating the Zacks Consensus Estimate of $2.96. Full year results were better than the year-ago earnings of $2.85. Strong growth in Europe, Asia-Pacific, the Americas and Japan helped fourth quarter revenues increase 14% to $874 million. Excluding the impact of currency and the divested Lab Information Management Software (LIMS) business, revenues grew 11%. Full year revenues increased 5% to $3.3 billion. All revenue segments at Life recorded an increase in sales during the fourth quarter. The Molecular Biology Systems division recorded a 19% increase in fourth quarter revenues, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/life-life-technologies-corporation-beats-expectations-outlook-positive/26320/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters Corporation Matches Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/26/wat-waters-corporation-matches-earnings-estimates/26077</link>
		<comments>http://www.stockbloghub.com/2010/01/26/wat-waters-corporation-matches-earnings-estimates/26077#comments</comments>
		<pubDate>Tue, 26 Jan 2010 22:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26077</guid>
		<description><![CDATA[Waters Corporation (WAT) reported earnings per share of $1.10, excluding restructuring charges, for the fourth quarter of 2009, which matched the Zacks Consensus Estimate. The company reported fourth quarter 2009 sales of $429 million, an increase of 3% from sales of $418 million in the fourth quarter of 2008. In the quarter, foreign currency translation increased the sales growth rate by 4%. For the full year, sales for the Company were $1.50 billion, a decrease of 5% from sales of $1.58 billion in 2008. This decrease in sales includes the effects of foreign currency translation, which reduced sales by 2%. Cash and cash equivalents were $630 million with long-term debt of $500 million and shareholders’ equity of $847 million. The company recently introduced the new Waters® ACQUITY UPLC® H-Class System ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/26/wat-waters-corporation-matches-earnings-estimates/26077/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199</link>
		<comments>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:15:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25199</guid>
		<description><![CDATA[Recently, we upgraded Luminex Corp. (LMNX) to Neutral from Underperform. Our decision to upgrade the stock was based on the company’s wide range of products and its significant international presence. These positive factors should drive growth in the coming quarters. Additionally, Luminex has an interesting pipeline. Should the pipeline develop successfully, the company can look at further growth. We are pleased with the company&#8217;s broad product portfolio. Luminex’s instrument base consists of the Luminex 100 (LX100), Luminex 200 (LX200) and FlexMap 3D systems. The Luminex 100 and 200 are compact analyzers that integrate fluidics, optics and digital signal processing to perform up to 100 bioassays simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. By combining small diode lasers with digital ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Posts Loss</title>
		<link>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552</link>
		<comments>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:36:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21552</guid>
		<description><![CDATA[Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was a gain of 7 cents. The loss in the quarter was attributable to the higher operating expenses which more than offset the increase in revenues. Total revenues for the reported quarter came in at $29.1 million as against $28.9 million in the year-ago period, up 1%. As per segments, revenues from the Technology segment came in at 22 million as against $22.6 million in the year-ago quarter. Assay group sales for the quarter came in at approximately $7.1 million, up 12% over the comparable quarter of 2008. Total ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters Corporation Modestly Outperforms</title>
		<link>http://www.stockbloghub.com/2009/10/28/wat-waters-corporation-modestly-outperforms/19043</link>
		<comments>http://www.stockbloghub.com/2009/10/28/wat-waters-corporation-modestly-outperforms/19043#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:29:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19043</guid>
		<description><![CDATA[Waters Corporation (WAT) reported third quarter 2009 revenues of $374 million, a decrease of 3% over that of $386 million in the third quarter of 2008. On a GAAP basis, earnings per diluted share for the third quarter were 79 cents, compared to 71 cents for the third quarter of 2008. This exceeded the Zacks Consensus Estimate of 77 cents per share. Business trends in the third quarter suggested a stabilization of demand by major end markets. Customer interest in new products is encouraging and indicates that research-related spending may benefit its future results. Through the first nine months of 2009, sales for the Company were $1.07 billion, a decrease of 8% in comparison to sales of $1.15 billion in the first nine months of 2008. Foreign currency translation contributed negatively to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/wat-waters-corporation-modestly-outperforms/19043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Corporation Beats</title>
		<link>http://www.stockbloghub.com/2009/10/27/life-life-technologies-corporation-beats/18934</link>
		<comments>http://www.stockbloghub.com/2009/10/27/life-life-technologies-corporation-beats/18934#comments</comments>
		<pubDate>Wed, 28 Oct 2009 01:42:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18934</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) reported third quarter earnings of 73 cents per share, well above the Zacks Consensus Estimate of 61 cents. The company reported earnings of 63 cents in the year-ago period. Strong growth in Europe, Asia-Pacific and Japan helped revenues increase 3% to $805 million. Excluding the impact of currency and the divested LIMS business, revenues grew 5%. Apart from the Cell Systems division, all other revenue segments at Life recorded an increase in sales. The Molecular Biology Systems division recorded a 5% increase in revenues, which came in at $394 million. Revenues were driven by demand across the portfolio Incorporatedluding continued strong orders for the company’s Influenza A (H1N1)-related products. Double-digit growth for consumable kits and capillary electrophoresis instruments sold into applied markets like forensics, continued growth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/27/life-life-technologies-corporation-beats/18934/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health&#8217;s Results Reveal Oncotype DX Utility</title>
		<link>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568</link>
		<comments>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:28:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Clarient Inc]]></category>
		<category><![CDATA[CLRT]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17568</guid>
		<description><![CDATA[Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer. Genomic Health&#8217;s Oncotype DX is the only commercially available breast cancer test that makes use of manual microdissection following review by a board certified surgical pathologist with expertise in breast cancer to predict a patient&#8217;s benefit from chemotherapy and risk of disease recurrence. The results from the study revealed that the inclusion of biopsy cavities in breast cancer specimens is associated with significant changes in the expression of individual genes. Consequently, it was found that biopsy cavities had high-risk Recurrence Scores. Genomic also presented results which demonstrated ability of Oncotype DX ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Good News for Genomic Health</title>
		<link>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460</link>
		<comments>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:17:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14460</guid>
		<description><![CDATA[Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health&#8217;s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options available at their maiden visit to an oncologist. Oncotype DX, the growth engine of the company, was launched in 2004. It is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In late May 2009, Genomic Health announced that more than 100,000 test results have been delivered in over 40 countries worldwide since the commercial launch of Oncotype DX. The assay analyzes the activity of 21 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DHR) Danaher Expands in Life Sciences</title>
		<link>http://www.stockbloghub.com/2009/09/02/dhr-danaher-expands-in-life-sciences/14196</link>
		<comments>http://www.stockbloghub.com/2009/09/02/dhr-danaher-expands-in-life-sciences/14196#comments</comments>
		<pubDate>Wed, 02 Sep 2009 19:44:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Conglomerates]]></category>
		<category><![CDATA[Danaher Corp.]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[MDZ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14196</guid>
		<description><![CDATA[Earlier today, Danaher Corp. (DHR) announced its decision to acquire the Analytical Technologies division of MDS Inc. (MDZ). This includes a 50% stake in Applied Biosystems/MDS Sciex joint venture (AB SCIEX), and a 100% ownership in the former Molecular Devices Corp. The company has also reached an agreement with Life Technologies Corp. (LIFE) to acquire the remaining 50% ownership position in AB SCIEX. AB SCIEX designs and manufactures mass spectrometers, highly sensitive and sophisticated instruments used by researchers and clinicians. It sells its products to academic and research institutions, pharmaceutical development labs primarily supporting clinical trials, testing and reference labs and hospitals. Molecular Devices is a bioresearch and analytical instrumentation company. Danaher will pay a total of $1.1 billion for a full ownership of both these businesses. The acquired businesses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/dhr-danaher-expands-in-life-sciences/14196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

